Inclisiran for Cardiovascular and Limb Event Prevention
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 6,000 (estimated)
- Sponsor
- Duke University · Other
This trial is looking for adults who have recently had a procedure to open blocked arteries. Participants will receive a treatment called inclisiran, which is an injection given twice a year to help prevent serious heart and limb issues.
You may be able to join if
- I am at least 18 years old.
- I have had a successful heart or leg artery procedure within the last 14 days.
- I have signed the consent form to participate in the study.
You may not be able to join if
- I have a planned future heart or leg artery procedure.
- I am currently using or plan to use a PCSK9 inhibitor during the study.
- I have previously received treatment with inclisiran.
- I am participating in another clinical study with experimental drugs or devices.
- I have serious liver disease or other serious health conditions that may affect my participation.
- I am pregnant or breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityV-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Loading trial locations…